Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: A phase 3 randomised, double-blind, placebo-controlled trial

The Lancet Neurology

Volumn 13, Issue 5, 2014, Pages 461-471

  Michelson, David ^a   Snyder, Ellen ^a   Paradis, Erin ^a   Chengan Liu, Mary ^a   Snavely, Duane B ^a   Hutzelmann, Jill ^a   Walsh, James K ^b   Krystal, Andrew D ^c   Benca, Ruth M ^d   Cohn, Martin ^e   Lines, Christopher ^a   Roth, Thomas ^f   Herring, W Joseph ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ST LUKE S HOSPITAL   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e Omnitrials   (United States)

^f HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SUVOREXANT;

AGED; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV-TR; DYSPEPSIA; EUROPE; FALLING; FATIGUE; FEMALE; HALLUCINATION; HUMAN; HYPNAGOGIC HALLUCINATION; HYPNOPOMPIC HALLUCINATION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PARASOMNIA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE VARIABLE; SIDE EFFECT; SLEEP TIME; SLEEP WALKING; SOMNOLENCE; SOUTH AFRICA; WESTERN HEMISPHERE; XEROSTOMIA;

ADULT; AGE FACTORS; AGED; AZEPINES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; OREXIN RECEPTORS; RETROSPECTIVE STUDIES; SLEEP INITIATION AND MAINTENANCE DISORDERS; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84898546938     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70053-5     Document Type: Article

References (32)

1. Riemann D, Spiegelhalder K, Espie C, et al. Chronic insomnia: clinical and research challenges-an agenda. Pharmacopsychiatry 2011, 44:1-14.
2. Morin CM, Benca R Chronic insomnia. Lancet 2012, 379:1129-1141.
3. Roehrs TA, Randall S, Harris E, Maan R, Roth T Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol 2012, 26:1088-1095.
4. Randall S, Roehrs TA, Roth T Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study. Sleep 2012, 35:1551-1557.
5. Mayer G, Wang-Weigand S, Roth-Schechter B, Lehmann R, Staner C, Partinen M Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep 2009, 32:351-360.
6. Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T Long-term efficacy and safety of zolpidem extended-release 12·5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 2008, 31:79-90.
7. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007, 30:959-968.
8. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003, 26:793-799.
9. Roehrs T, Roth T Insomnia pharmacotherapy. Neurotherapeutics 2012, 9:728-738.
10. Sakurai T, Mieda M, Tsujino N The orexin system: roles in sleep/wake regulation. Ann NY Acad Sci 2010, 1200:149-161.
11. Gotter AL, Roecker AJ, Hargreaves R, Coleman PJ, Winrow CJ, Renger JJ Orexin receptors as therapeutic drug targets. Prog Brain Res 2012, 198:163-188.
12. Cox CD, Breslin MJ, Whitman DB, et al. Discovery of the dual orexin receptor antagonist[(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 2010, 53:5320-5332.
13. Winrow CJ, Gotter AL, Cox CD, et al. Promotion of sleep by MK-4305-a novel dual orexin receptor antagonist. J Neurogenet 2011, 25:52-61.
14. Sun H, Kennedy WP, Wilbraham D, et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep 2013, 36:259-267.
15. Herring WJ, Snyder E, Budd K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 2012, 79:2265-2274.
16. Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, American Psychiatric Association, Washington, DC. 4th edn.
17. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011, 168:1266-1277.
18. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003, 54:573-583.
19. Tyrer P, Murphy S, Riley P The benzodiazepine withdrawal symptom questionnaire. J Affect Disord 1990, 19:53-56.
20. Ott H, Oswad I, Fichte K, Sastre Y, Hernandez M VIS-A und VIS-M. Collegium Internationale Psychiatria-Scalarum 1996, Beltz Test GmbH, Weinheim.
21. Guy W ECDEU Assessment manual for psychopharmacology. Publication No 76-338 1976, National Institutes of Health, Rockville, MD.
22. Bastien CH, Vallieres A, Morin CM Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001, 2:297-307.
23. Entsuah R ETRANK: a ranking procedure for handling missing data in clinical trials: application to venlafaxine extended-release depression clinical trial. J Biopharm Stat 1996, 6:457-475.
24. Ambien (zolpidem) prescribing information, updated April 2013 Sanofi-Aventis, (accessed May 1, 2013). http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019908s032s034,021774s013s015lbl.pdf.
25. Restoril (temazepam) prescribing information, updated Nov 4, 2010 Mallinckrodt Inc, (accessed May 1, 2013). http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018163s054lbl.pdf.
26. Sonata (zaleplon) prescribing information updated August 2011 King Pharmaceuticals Inc, (accessed May 1, 2013). http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020859s013lbl.pdf.
27. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39-40.
28. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 6:991-997.
29. Black SW, Morairty SR, Fisher SP, Chen TM, Warrier DR, Kilduff TS Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy. Sleep 2013, 36:325-336.
30. Connor K, Budd K, Snavely D, et al. Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: results from the first of two 3-month pivotal phase 3 trials. J Sleep Res 2012, 21(suppl 1):97.
31. Ivgy-May N, Leibensperger H, Froman S, et al. Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: results from the second of two 3-month pivotal phase 3 trials. J Sleep Res 2012, 21(suppl 1):351-352.
32. Farkas R FDA presentations for the May 22, 2013 meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (accessed Feb 26, 2014). http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/ucm346581.htm.